Renal Transplantation Linked to Improved Survival for ESRD Due to Granulomatosis With Polyangiitis
Renal transplantation is associated with a significant decrease in mortality among patients with end-stage renal disease attributed to granulomatosis with polyangiitis.
Individually Tailored vs Fixed-Schedule Rituximab Regimens in ANCA-Associated Vasculitis
Results of the MAINRITSAN2 trial show that ANCA-associated vasculitides relapse rates did not differ significantly among patients treated with individually tailored vs fixed-schedule rituximab infusion regimens.
Takayasu Arteritis: Efficacy and Safety of Tocilizumab vs Placebo
Tocilizumab therapy improves time to relapse in Takayasu arteritis with a favorable safety and tolerability profile.
Large Vessel Vasculitis Imaging: Recommendations for Clinical Practice
EULAR has released 12 evidence-based recommendations for the use of imaging in the diagnosis and monitoring of large vessel vasculitis, including giant cell arteritis and Takayasu arteritis.
First Treatment for Eosinophilic Granulomatosis With Polyangiitis Approved by FDA
The FDA has expanded the approval of mepolizumab for treating eosinophilic granulomatosis with polyangiitis, which causes vasculitis.
Azathioprine With Glucocorticoids in Nonsevere Systemic Necrotizing Vasculitides
Adding azathioprine to glucocorticoids has no significant benefit for patients with nonsevere systemic necrotizing vasculitides.
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Biomarkers Identified
Several circulating biomarkers for antineutrophil cytoplasmic antibody-associated vasculitis disease activity and organ involvement were identified using targeted serum proteomics.
Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis
Central airway disease and a nodular pattern of pulmonary involvement occurred significantly more often in PR3-ANCA-positive patients than in MPO-ANCA-positive patients.
Increased Cardiovascular Risk Factor Prevalence in Takayasu's Arteritis
The risk for cardiovascular events was higher in patients with Takayasu's arteritis.
FDA Approves First Drug to Specifically Treat Giant Cell Arteritis
Actemra (tocilizumab) has been FDA-approved for its use in giant cell arteritis treatment.
Rheumatology Advisor Articles
- Baricitinib Shows Positive Results for Systemic Lupus Erythematosus in Phase 2 Study
- Bimekizumab Linked to 12-Week Clinical Improvements in Ankylosing Spondylitis
- Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis
- Sprifermin Improved Cartilage Morphology, Thickness in Knee Osteoarthritis
- Poverty, Neighborhood May Affect Outcomes in Systemic Lupus Erythematosus
- Examining the Therapeutic Possibilities of Nutrition in Fibromyalgia
- Managing Cognitive Dysfunction in Systemic Lupus Erythematosus
- Sex-Based Differences in Rheumatoid Arthritis: Clinical Implications and Patient Management
- False-Positive Tuberculin Skin Test Results Linked to Methotrexate Therapy
- Poverty, Neighborhood May Affect Outcomes in Systemic Lupus Erythematosus
- Addressing Confidentiality Concerns With Electronic Access to Pediatric Medical Records
- Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women
- Multisystem Intervention Reduces Missed Opportunities for Influenza Vaccination in RA
- How Is Attending Physician Supervision Linked to Resident, Intern Medical Error Rate?
- PAH in Systemic Sclerosis Increases Risk for Early Mortality